Serum waives AstraZeneca shooting allowance for refugee program


(Reuters) – The Serum Institute of India has waived its protection against legal liabilities for any AstraZeneca-Oxford COVID-19 vaccine it supplies to a global refugee program, a spokesperson for the Reuters told Reuters on Wednesday. alliance for GAVI vaccines.

The news comes days after Reuters reported that tens of millions of migrants could be denied COVID-19 vaccines from the COVAX vaccine sharing program over concerns over who would be responsible for harmful side effects. .

Many manufacturers of COVID-19 vaccines are demanding that countries compensate them for any adverse events suffered by individuals as a result of the vaccines. But where governments do not control – in the case of refugees – it is not possible.

With the waiver, the SII version of the AstraZeneca-Oxford vaccine, Covishield, can now be allocated to the COVAX humanitarian buffer – a reserve of last-resort vaccines to be distributed by humanitarian groups, the GAVI representative said.

SII, the world’s largest vaccine maker that also produces a version of Novavax’s COVID-19 vaccine, declined to comment.

AstraZeneca-Serum are currently the main suppliers of COVID-19 vaccines to COVAX, but are expected to be replaced by Pfizer and BioNTech in early 2022.

GAVI, a public-private partnership, was created in 2000 to promote immunization around the world. It operates COVAX with the World Health Organization to deliver COVID-19 vaccines to the poorest countries.


About Author

Comments are closed.